In the pooled analysis , @ of @ patients ( @ % ) in the dalbavancin group and @ of @ ( @ % ) in the vancomycin-linezolid group had an early clinical response indicating treatment success ( weighted difference , -@ percentage point ; @ % confidence interval , -@ to @ ) .